Subscribe to Search results

Pete Longstaff refused human derived Factor 8 products in a treatment strike which lasted until his death.

Published on:

Recombinant Factor 9 was licensed and the funding arrangements in England mirrored those for Factor 8.

Published on:

Charles Lister wrote to Nick Raisen regarding synthetic blood products.

Published on:

By this date all patients with Haemophilia in Scotland were being treated with recombinant Factor 8 or 9.

Published on:

By this date it had been confirmed that in Northern Ireland recombinant Factor 8 would be funded for all patients.

Published on:

Individuals were still experiencing issues with equal access to recombinant Factor 8 as a result of funding.

Published on:

It was not until the financial year 2004/2005 that all patients with Haemophilia A, of whatever age, had access to recombinant Factor 8.

Published on:

Judith Paget explained children in Wales can receive recombinant von Willebrand Factor off-label for on-demand treatment of non-surgical and surgical bleeding episodes.

Published on:

Caroline Lamb explained children in Scotland can receive recombinant von Willebrand Factor if appropriate.

Published on:

In Northern Ireland, access to recombinant blood products for children with von Willebrand disorder is available in exceptional cases through the Individual Funding Request ("IFR") route, however to date no IFR has been made.

Published on:

Daniel Eve explained NHS England funded off-label usage of recombinant blood products for post-pubertal children with Von Willebrand Disease. NHS England is in the early stages of considering the possibility of off-label usage for patients under 12.

Published on:

An article on the variation in Hepatitis C services in the UK was published, which found that the majority of patients were not receiving antiviral treatment, in contrast with practice in Europe.

Published on:

Clinical guidelines on the management of hepatitis C were published.

Published on:

World Health Organisation Fact Sheet on Palliative Care defined palliative care as an approach that improves the quality of life of patients facing problems associated with life threatening illness.

Published on:

The psychosocial expert group reported to the Inquiry that a breakdown in trust between a patient and healthcare provider has been shown to have deleterious effects on quality of care across all serious health problems. Having to continue attending for healthcare in the treatment setting where the infected blood had been given was clearly "a major source of distress for many individuals."

Published on:

Jean Smith explained the difficulties she encountered in accessing treatment for Hepatitis C.

Published on:

A witness explained the difficulties she experienced in accessing treatment for Hepatitis C.

Published on:

A witness found that when her brother was dying "There was no palliative care in place; none of the medical team spoke to our mother, nor me or my sister."

Published on:

The Department of Health maintained in their response to campaigners that "it is for clinicians to decide whether to use plasma-based factor VIII or recombinant factor VIII."

Published on:

The Recombinant Factor VIII Users' Group was formed. It consisted of haemophilia centre directors prescribing recombinant Factor 8.

Published on: